ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 450

Injection Site Reaction Associated with Subcutaneous Biologic Agents and Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry

Denis Choquette1, Louis Bessette2, Jacques Brown2, Boulos Haraoui1, Frédéric Massicotte1, Jean-Pierre Pelletier1, Jean-Pierre Raynauld1, Marie-Anaïs Rémillard1, Diane Sauvageau1, Angèle Turcotte2, Édith Villeneuve1 and Louis Coupal1, 1Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, 2Rheumatology, Centre de l'Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), pain, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Pain Mechanisms – Basic and Clinical Science Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Injection Site Reaction (ISRs) are associated with the subcutaneous (SC) route of administration of all biologic agents, and 3% to 15% of patients reports it. ISRs include pain, itching, redness, swelling or a combination of any of those. Rhumadata® has collected the intensity of pain associated with SC injections. We report here the results and compare levels of pain across agents.

Methods: As part of the patient reported outcomes (PROs), one question on pain intensity was asked to patients exposed to SC methotrexate or a biologic agent administered with a device or a syringe. The same question was asked at all visits making multiple answers available for the same patient. The intensity of pain was described using the following scale: 1- none, 2- negligible, 3- mild, 4- moderate, 5- severe, 6- extremely severe and 7- intolerable. Pain levels associated with adalimumab (ADA), etanercept (ETA), certolizumab (CERTO), golimumab (GOLI), denosumab (DEN), abatacept (ABA), tocilizumab (TOCI) and methotrexate (MTX) are presented.

Results: A total of 12,843 injection pain assessments were extracted. 7,347, 2,117 and 3,319 were performed on patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) respectively. Women represented 76%, 44% and 50% of these cohorts. Mean ages at treatment initiation were 53.0(SD=12.1), 41.6(12.4) and 48.7(11.6). Severe, very severe or intolerable pain was reported for 3.12%, 9.23% and 6.21% of SC injections performed on patients with RA, AS and PsA respectively. Multivariate logistic regression showed that women (OR=2.09, 95% CI=[1.42, 3.08]) were more likely to report severe, very severe or intolerable pain than men, as were patients with longer disease duration (OR=1.04, 95% CI=[1.02, 1.06]). Patients diagnosed later (Age at diagnosis OR=0.98, 95% CI=[0.97, 1.00]) were less likely to report high levels of pain. Subjects treated with ADA (OR=6.31, 95% CI=[3.13, 12.72]) and ETA (OR=4.37, 95% CI=[2.42, 7.90]) were more likely to report more pain than patients using MTX. Patients using CERTO (OR=0.26, 95% CI=[0.12, 0.54]) and GOLI (OR=0.11, 95% CI=[0.06, 0.23]) were less likely to report severe, very severe and intolerable pain than patients injected with ADA. Primary diagnosis (RA, AS and PsA) are similarly associated with reported pain levels. Stopping MTX or bDMARD treatment for an ISR-pain is extremely rare.

Conclusion: The intensity of pain associated with subcutaneous route of administration varies with gender, age (age at diagnosis and disease duration at injection) and administered medication.


Disclosure: D. Choquette, None; L. Bessette, None; J. Brown, None; B. Haraoui, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Merck, Pfizer, Roche, and UCB, 2, 5, 8; F. Massicotte, None; J. P. Pelletier, None; J. P. Raynauld, None; M. A. Rémillard, None; D. Sauvageau, None; A. Turcotte, None; É. Villeneuve, None; L. Coupal, None.

To cite this abstract in AMA style:

Choquette D, Bessette L, Brown J, Haraoui B, Massicotte F, Pelletier JP, Raynauld JP, Rémillard MA, Sauvageau D, Turcotte A, Villeneuve É, Coupal L. Injection Site Reaction Associated with Subcutaneous Biologic Agents and Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/injection-site-reaction-associated-with-subcutaneous-biologic-agents-and-methotrexate-analysis-from-the-rhumadata-clinical-database-and-registry/. Accessed January 28, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/injection-site-reaction-associated-with-subcutaneous-biologic-agents-and-methotrexate-analysis-from-the-rhumadata-clinical-database-and-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences